Viral treatment
US11819534B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 27, 2019 |
| Grant date | Nov 21, 2023 |
| Priority date | — |
| Expiry date | Jun 12, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides molecules for use in compositions, medicaments and methods for the treatment or prevention of RSV infections, its symptoms and associated pathologies and potentially infections caused or contributed to by viral pathogens which do not bind or do not primarily bind sialic acid containing receptors during pathogenesis. Specifically, the disclosure is based on the finding that molecules with affinity for (or an ability to bind to) sialic acid (and in particular sialoglycoconjugates) on cell surfaces (these including sialic acid containing glycoproteins and cell surface sialic acid receptors), find utility in the treatment and/or prevention of symptoms, infections, diseases and/or conditions associated with respiratory syncytial vims (RSV).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.